[go: up one dir, main page]

ES2110008T3 - Dermatan sulfato que posee una actividad trombolitica y formulaciones farmaceuticas que lo contienen - Google Patents

Dermatan sulfato que posee una actividad trombolitica y formulaciones farmaceuticas que lo contienen

Info

Publication number
ES2110008T3
ES2110008T3 ES92916443T ES92916443T ES2110008T3 ES 2110008 T3 ES2110008 T3 ES 2110008T3 ES 92916443 T ES92916443 T ES 92916443T ES 92916443 T ES92916443 T ES 92916443T ES 2110008 T3 ES2110008 T3 ES 2110008T3
Authority
ES
Spain
Prior art keywords
activity
sulfate
thrombolitic
possesses
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92916443T
Other languages
English (en)
Inventor
Giuseppe Mascellani
Pietro Bianchini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opocrin SpA
Original Assignee
Opocrin SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opocrin SpA filed Critical Opocrin SpA
Application granted granted Critical
Publication of ES2110008T3 publication Critical patent/ES2110008T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UN SULFATO DE DERMATAN NATURAL QUE POSEE UNA ACTIVIDAD ANTITROMBINICA EN EXCESO DE 200 U/MG, Y QUE SE CARACTERIZA PORQUE SE COMPONE DE UNA SECUENCIA DE OLIGOSACARIDOS CON UN ALTO GRADO DE SULFATACION, QUE TIENE LA FORMULA (III) EN LA QUE: N = ENTEROS 1 O 2; R4 = SO3 CO; I URONICO, EXTRAIDO DE ORGANOS Y PURIFICADO POSTERIORMENTE BAJO CONDICIONES DE TRATAMIENTO SUAVES, A UN PH ENTRE 5 Y 7 O EN CUALQUIER CASO INFERIOR A 7, LLEVANDOSE A CABO LA SEPARACION Y FRACCIONAMIENTO CON RESINAS INTERCAMBIADORAS DE IONES MACRORRETICULARES QUE TIENE UN TAMAÑO DE PARTICULA DE 0,3 A 1,3 MM, E INCLUSO INFERIOR A 10 (MU).
ES92916443T 1991-08-28 1992-08-06 Dermatan sulfato que posee una actividad trombolitica y formulaciones farmaceuticas que lo contienen Expired - Lifetime ES2110008T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI912310A IT1251183B (it) 1991-08-28 1991-08-28 Dermatan solfato ad alto titolo, dotato di elevata attivita' trombolitica, e forme farmaceutiche che lo contengono.

Publications (1)

Publication Number Publication Date
ES2110008T3 true ES2110008T3 (es) 1998-02-01

Family

ID=11360588

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92916443T Expired - Lifetime ES2110008T3 (es) 1991-08-28 1992-08-06 Dermatan sulfato que posee una actividad trombolitica y formulaciones farmaceuticas que lo contienen

Country Status (12)

Country Link
US (1) US5547944A (es)
EP (1) EP0600928B1 (es)
JP (1) JP3279316B2 (es)
KR (1) KR100233338B1 (es)
AT (1) ATE160149T1 (es)
AU (1) AU2396292A (es)
CA (1) CA2116437A1 (es)
DE (1) DE69223153T2 (es)
DK (1) DK0600928T3 (es)
ES (1) ES2110008T3 (es)
IT (1) IT1251183B (es)
WO (1) WO1993005074A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
PL177245B1 (pl) * 1993-09-30 1999-10-29 Seikagaku Kogyo Co Ltd Środek przeciwzakrzepowy
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
AU4938397A (en) * 1996-12-24 1998-07-17 Hyal Pharmaceutical Corporation Methods of elevating amounts of hyaluronan in the human body
GB9711443D0 (en) * 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
FI974321A0 (fi) 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
US6409987B1 (en) 1999-04-07 2002-06-25 Intimax Corporation Targeted agents useful for diagnostic and therapeutic applications
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
US20050164983A1 (en) * 2003-12-19 2005-07-28 Aventis Pharma S.A. Carboxyl-reduced derivatives of dermatan sulfate, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them
AU2005243161A1 (en) * 2004-05-11 2005-11-24 Heptest Laboratories, Inc. Compositions, kit and one-step method for monitoring compounds having anti-factor Xa and/or anti factor iia activities

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3124384C2 (de) * 1981-06-22 1985-05-15 Herbert Prof. Dr. 1000 Berlin Voß Dermatanpolysulfat, Verfahren zu dessen Herstellung und dieses enthaltendes virushemmendes Mittel
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
IT1189085B (it) * 1986-03-25 1988-01-28 Mediolanum Farmaceutici Srl Processo per la preparazione di dermatan solfato ad alta purezza e composizioni farmaceutiche che lo contengono
WO1991015217A1 (en) * 1990-04-06 1991-10-17 Washington University Anticoagulant oligosaccharides

Also Published As

Publication number Publication date
JPH06510081A (ja) 1994-11-10
EP0600928B1 (en) 1997-11-12
ITMI912310A0 (it) 1991-08-28
CA2116437A1 (en) 1993-03-18
EP0600928A1 (en) 1994-06-15
DE69223153D1 (de) 1997-12-18
KR100233338B1 (ko) 1999-12-01
IT1251183B (it) 1995-05-04
US5547944A (en) 1996-08-20
ITMI912310A1 (it) 1993-02-28
WO1993005074A1 (en) 1993-03-18
ATE160149T1 (de) 1997-11-15
DK0600928T3 (da) 1998-07-27
AU2396292A (en) 1993-04-05
DE69223153T2 (de) 1998-03-05
JP3279316B2 (ja) 2002-04-30

Similar Documents

Publication Publication Date Title
ES2110008T3 (es) Dermatan sulfato que posee una actividad trombolitica y formulaciones farmaceuticas que lo contienen
NO954281L (no) Vannrensesystem
DE69636620D1 (de) Expression von saccharose phosphorylase in pflanzen
BR8707452A (pt) Implante de enxerto osseo
SE9500538D0 (sv) Fragment Clamp/buttress
NO953853L (no) Aminosukker og glykosaminglykansammensetning for behandling og reparasjon av bindevev
ES2190447T3 (es) Pañal desechable.
ATE357452T1 (de) Sialyl-lewisa und sialyl lewisx epitop-analoge
FI944231L (fi) Antitromboottiset tripeptidiaineet
NO975557D0 (no) Immortalisering og dismortalisering av celler
CA2016575A1 (en) Method of aiding cessation of smoking
SE8401201L (sv) Farmaceutisk beredning
ATE265861T1 (de) Antikörper gegen l-selectin zur vorbeugung von multiplem organversagen und akuter organschädigung
AR014119A1 (es) Utilizacion de cetolidas para la fabricacion de composiciones farmaceuticas destinadas a prevenir complicaciones tromboticas arteriales asociadas a laaterosclerosis
BR9611324A (pt) Remoção de cáustico na hemicelulose cáustica
DK0831722T3 (da) Gelsystem, som omfatter carrageenan og kokosnødendosperm
ZA915587B (en) Rinse-free shampoo
AU7166187A (en) Optimal parametric signal processor
ES284716U (es) Juguete de edificacion o construccion perfeccionado.
RO88332A2 (ro) Soi de mazare de gradina(pisum sativum l,var medullare allee)"islanita 60"
ITMI942076A0 (it) Procedimento per la riduzione del contenuto di nicotina mediante l'azione di microrganismi
AU8132682A (en) Surgical :in-line: evacuator
ES2112735A1 (es) Recipiente colector moldeado por inyeccion de materia plastica y procedimiento para su fabricacion.
NO874634D0 (no) Optimalisert parametrisk signalprosessor.
BG96610U (bg) Тонизиращо средство

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 600928

Country of ref document: ES